BDBM359563 (R or S)-4-(6-((2- (1H-imidazol-1- yl)ethyl)(methyl)car- bamoyl)-1-(2-chloro- 6-(1- (trifluoromethyl)cyclo- propyl)benzoyl)- 4,5,6,7-tetrahydro- 1H-indazol-3-yl)-3- fluorobenzoic acid::US10221142, Example 21CC

SMILES CN(CCn1ccnc1)C(=O)C1CCc2c(C1)n(nc2-c1ccc(cc1F)C(O)=O)C(=O)c1c(Cl)cccc1C1(CC1)C(F)(F)F

InChI Key InChIKey=HFGBBJCTFFLSPK-UHFFFAOYSA-N

Data  1 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 359563   

TargetNuclear receptor ROR-gamma(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM359563((R or S)-4-(6-((2- (1H-imidazol-1- yl)ethyl)(methy...)
Affinity DataIC50: 1.40nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent